Cardax Inc
OTC:CDXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cardax Inc
Cash
Cardax Inc
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardax Inc
OTC:CDXI
|
Cash
$19.2k
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash
$3.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cardax Inc
Glance View
Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.
See Also
What is Cardax Inc's Cash?
Cash
19.2k
USD
Based on the financial report for Dec 31, 2020, Cardax Inc's Cash amounts to 19.2k USD.
What is Cardax Inc's Cash growth rate?
Cash CAGR 5Y
-43%
Over the last year, the Cash growth was -1%. The average annual Cash growth rates for Cardax Inc have been -80% over the past three years , -43% over the past five years .
